Health Canada12 Aug 2026
pms-IRBESARTAN: Affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets.
Health Canada published a recall notice for pms-IRBESARTAN: Affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets on 12 Aug 2026. It is one of 311 notices of this kind from Health Canada since 2 Apr 2026 in AreaZine's record.
Recall
The recall notice
- Issued by
- Health Canada
- Issued
- 12 Aug 2026
- Recall type
- Health product recall
- Companies
- Pharmascience Inc.6111 avenue Royalmount, suite 100, MontréalQC H4P 2T4
- Official source
- Health Canada: the notice at its source
The latest from Health CanadaEvery warning and recall in Canada
Source: Health Canada: the notice at its source. AreaZine rebuilds this page from the agency's record; the agency's page is the one to act on. Contains information licensed under the Open Government Licence – Canada.
The notice as issued
Issue: The affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets. What you should do What to do: Verify whether your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada. Additional information Background Affected products: Brand Product Name Market Authorization Dosage Form Strength Lot Number Pharmascience Inc. pms-IRBESARTAN DIN 02317079 Tablet 150 mg 667278 Issue
Source: Health Canada: the notice at its source. The text is the agency's, unedited. Contains information licensed under the Open Government Licence – Canada.